Souvik Mukherjee

Dr. Souvik Mukherjee

research scholar Department of pharmaceutical sciences, Guru Ghasidas Central University, Bilaspur, India
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in Membranes
Verified
Journal Article
Open access
PDF file
Souvik MukherjeeSouvik Mukherjee
Souvik Mukherjee
ASABDULAZIZ SAEEDAN
ABDULAZIZ SAEEDAN
Mohd Nazam AnsariMohd Nazam Ansari
Mohd Nazam Ansari
MSManjari Singh
Manjari Singh
Particular dramatic macromolecule proteins are responsible for various cellular events in our body system. Lipids have recently recognized a lot more attention of scientists for understanding the relationship between lipid and cellular function and human health However, a biological membrane is formed with a lipid bilayer, which is called a P–L–P design. Our body system is balanced through various communicative signaling pathways derived from biological membrane proteins and lipids. In the case of any fatal disease such as cancer, the biological membrane compositions are altered. To repair the biological membrane composition and prevent cancer, dietary fatty acids, such as omega-3 polyunsaturated fatty acids, are essential in human health but are not directly synthesized in our body system. In this review, we will discuss the alteration of the biological membrane composition in breast cancer. We will highlight the role of dietary fatty acids in altering cellular composition in the P–L–P bilayer. We will also address the importance of omega-3 polyunsaturated fatty acids to regulate the membrane fluidity of cancer cells.

14 January 2021 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
DPDilipkumar Pal
Dilipkumar Pal
Souvik MukherjeeSouvik Mukherjee
Souvik Mukherjee
ISIn-Ho Song
In-Ho Song
Satish Balasaheb NimseSatish Balasaheb Nimse
Satish Balasaheb Nimse
: Alzheimer's disease (AD), a chronic neurodegenerative disease, is the most common form of dementia that causes cognitive function impairment, including memory, thinking, and behavioral changes that ultimately lead to death. The over activation of GSK-3, an enzyme from the proline/serine Ki NS family, has been associated with hyper-phosphorylation of tau proteins. Hyper-phosphorylated tau proteins self-assemble to form tangles of straight and helical filaments are known to be involved in AD. Therefore, GSK-3 has been considered a potential target of novel drug discovery for AD treatment. The research on the development of GSK-3 inhibitors has received enormous attention from the vast scientific community because they are targeted for AD and other diseases, including type 2 diabetes, cancers, stroke, Parkinson's disease, bipolar disorder etc. Various drugs originated from synthetic and natural origins have been designed to inhibit GSK-3 activity. However, there is a need to develop novel drug candidates that are selective in the inhibition of GSK3. Hence, this review summarizes the potential of GSK-3 inhibitors for AD therapy. The structure-activity relationship of current drug molecules and the potential problems associated with them are discussed in detail.

1 January 2020
Verified
Book Chapter
Closed access
DPDilipkumar Pal
Dilipkumar Pal
Souvik MukherjeeSouvik Mukherjee
Souvik Mukherjee

1 January 2020
Verified
Book Chapter
Closed access
DPDilipkumar Pal
Dilipkumar Pal
Souvik MukherjeeSouvik Mukherjee
Souvik Mukherjee

1 April 2021 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
Souvik MukherjeeSouvik Mukherjee
Souvik Mukherjee
KCKavi Bhushan Singh Chouhan
Kavi Bhushan Singh Chouhan
RTRoshni Tandey
Roshni Tandey
NYNeelima Yadav
Neelima Yadav
MDMahaveer Dhobi
Mahaveer Dhobi
VMVivekananda Mandal
Vivekananda Mandal

8 September 2024 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
SBsubhasis banerjee
subhasis banerjee
Souvik MukherjeeSouvik Mukherjee
Souvik Mukherjee
MKMohsin Kazi
Mohsin Kazi
KSKalyan Kumar Sen
Kalyan Kumar Sen
ADArka Das
Arka Das
MAMohd Fahami Nur Azlina
Mohd Fahami Nur Azlina
The present study deals with the in-silico analyses of several flavonoid derivatives to explore COVID-19 through pharmacophore modelling, molecular docking, molecular dynamics, drug-likeness, and ADME properties. The initial literature study revealed that many flavonoids, including luteolin, quercetin, kaempferol, and baicalin may be useful against SARS β-coronaviruses, prompting the selection of their potential derivatives to investigate their abilities as inhibitors of COVID-19. The findings were streamlined using in silico molecular docking, which revealed promising energy-binding interactions between all flavonoid derivatives and the targeted protein. Notably, compounds 8, 9, 13, and 15 demonstrated higher potency against the coronavirus Mpro protein (PDB ID 6M2N). Compound 8 has a -7.2 Kcal/mol affinity for the protein and binds to it by hydrogen bonding with Gln192 and π-sulfur bonding with Met-165. Compound 9 exhibited a significant interaction with the main protease, demonstrating an affinity of -7.9 kcal/mol. Gln-192, Glu-189, Pro-168, and His-41 were the principle amino acid residues involved in this interaction. The docking score for compound 13 is -7.5 Kcal/mol, and it binds to the protease enzyme by making interactions with Leu-41, π-sigma, and Gln-189. These interactions include hydrogen bonding and π-sulfur. The major protease and compound 15 were found to bind with a favourable affinity of -6.8 Kcal/mol. This finding was further validated through molecular dynamic simulation for 1ns, analysing parameters such as RMSD, RMSF, and RoG profiles. The RoG values for all four of the compounds varied significantly (35.2–36.4). The results demonstrated the stability of the selected compounds during the simulation. After passing the stability testing, the compounds underwent screening for ADME and drug-likeness properties, fulfilling all the necessary criteria. The findings of the study may support further efforts for the discovery and development of safe drugs to treat COVID-19.